esophageal-squamous-cell-carcinoma

Documents about esophageal-squamous-cell-carcinoma

• Circular RNAs in esophageal squamous cell carcinoma: What do we know so far?#399660NCBI PubMed Central
• Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC.#981186ClinicalTrials.gov
• A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)#909537ClinicalTrials.gov
• A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer#992516ClinicalTrials.gov
• Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer#869607ClinicalTrials.gov
• Tislelizumab efficacy and safety compared to other anti–PD-1s: a network meta-analysis of first-line therapies for unresectable, locally advanced or metastatic esophageal squamous cell carcinoma#159320HAL (France)
• Hormonal Factors and Risks of Esophageal Squamous Cell Carcinoma and Adenocarcinoma in Postmenopausal Women#384234CiNii
• A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC#898451ClinicalTrials.gov
• A Study of Participants With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab as Part of an Early Access to Medicines Scheme (EAMS) Program in the United Kingdom#1031124ClinicalTrials.gov
• A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States#858280ClinicalTrials.gov
• The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC#862490ClinicalTrials.gov
• Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma#836922ClinicalTrials.gov
• The Impact of Two-field or Three-field Lymphadenectomy on Overall Survival in Middle and Lower Thoracic Esophageal Squamous Cell Carcinoma: An Observational Study#1031355ClinicalTrials.gov
• Anti-PD-1 Immunotherapy Combined With SBRT for Patients With Oligometastatic ESCC#208467ClinicalTrials.gov
• Adebrelimab Combined With Albumin Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable ESCC#366613ClinicalTrials.gov
• To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCC#913346ClinicalTrials.gov
• Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal Cancer#1007380ClinicalTrials.gov
• Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC#261523ClinicalTrials.gov
• Positron Emission Tomography in Determining Stage of Esophageal Cancer#853566ClinicalTrials.gov
• Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy#140999ClinicalTrials.gov
• PPIO-007 Correlation Analysis of Type II Diabetes Mellitus on Short-term and Long-term Outcomes of Patients With Esophageal Squamous Cell Cancer Undergoing Minimally Invasive Esophagectomy#67809ClinicalTrials.gov
• Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC#849286ClinicalTrials.gov
• Comparison of Nab-Paclitaxel Versus Paclitaxel in Neoadjuvant Immunochemotherapy Therapy for Esophageal Squamous Cell Carcinoma: A Retrospective IPTW-Adjusted Analysis#877474ClinicalTrials.gov
• Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC#914641ClinicalTrials.gov
• Prognosis and risk factors for pathological non-response to neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell carcinoma.#182482NCBI PubMed Central
• Peripheral Blood Biomarkers for Predicting the Efficacy of Neoadjuvant Immunochemotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma.#483370NCBI PubMed Central
• Trajectory Analysis of NLR and Its Association With Efficacy of Immunochemotherapy in ESCC.#640577ClinicalTrials.gov
• Immunotherapy Combined With Chemoradiotherapy for First-line Treatment of Esophageal Squamous Cell Carcinoma（ChinECR）#802422ClinicalTrials.gov
• Observational Study of Incidence Rates of Esophageal Cancer in Women Taking Medications for the Prevention or Treatment of Osteoporosis (MK-0217A-352)#1029798ClinicalTrials.gov
• Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC#162460ClinicalTrials.gov
• Association of stromal tumor infiltrating lymphocytes and body mass index with prognosis in esophageal squamous cell carcinoma patients.#185921NCBI PubMed Central
• PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis.#193779NCBI PubMed Central
• Urban-rural disparities in survival of Chinese esophageal squamous cell carcinoma: a cohort study of 133,064 cases.#340695NCBI PubMed Central
• Evolving Role of Immunotherapy in Advanced Esophageal Squamous Cell Carcinoma: Are Programmed Death-Ligand 1 (PD-L1) Cutoffs Still Relevant?#975614NCBI PubMed Central
• Efficacy and Safety of Tislelizumab Plus Chemotherapy as Conversion Therapy in Unresectable Locally Advanced ESCC#994848ClinicalTrials.gov
• Utility and Usability of ActivSight™ Laser Speckle Imaging in Visualization of Tissue Perfusion and Blood Flow During Esophageal Surgery in Humans#916458ClinicalTrials.gov
• Quantitative Assessment of Blood Supply in the Gastic Conduit With Fluorescence Angiography for Esophageal Reconstruction#827426ClinicalTrials.gov
• To Compare the Effect of Different Nutritional Pathways on Improving Nutritional Status of Esophageal Cancer Patients Undergoing Chemoradiotherapy#905798ClinicalTrials.gov
• A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.#886504ClinicalTrials.gov
• Neoadjuvant Docetaxel and Cisplatin Plus Chemoradiotherapy Followed By Surgery in Treating Patients With Locally Advanced, Resectable Esophageal Cancer#833470ClinicalTrials.gov
• Bone marrow mesenchymal stem cell-derived exosomal miR-93-5p suppresses esophageal squamous cell carcinoma progression and immune escape through targeting PD-L1.#685690NCBI PubMed Central
• Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer#1033128ClinicalTrials.gov
• Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Adjuvant Chemotherapy in the Treatment of the Lymph Node Positive Thoracic Esophageal Squamous Cell Carcinoma#903961ClinicalTrials.gov
• Swallowable Sponge Cell Sampling Device and Next Generation Sequencing in Detecting Esophageal Cancer in Patients With Low or High Grade Dysplasia, Barrett Esophagus, or Gastroesophageal Reflux Disease#843377ClinicalTrials.gov
• Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer#982454ClinicalTrials.gov
• Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC#172313ClinicalTrials.gov
• Real-world Experience of ICIs Plus Chemotherapy With or Without Radiotherapy for Advanced ESCC.#201797ClinicalTrials.gov
• Camrelizumab plus nimotuzumab as second-line therapy for advanced esophageal squamous cell carcinoma: a multicenter phase II study#784043Deutsche Nationalbibliothek
• Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)#872189ClinicalTrials.gov
• Advocating for Precision Neoadjuvant and Subsequent Adjuvant Therapies in Esophageal Squamous Cell Carcinoma: Evidence From a Real-World Multicenter Study.#457436NCBI PubMed Central